Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 25, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...

The transient receptor potential vanilloid (TRPV1) ion channel is a polymodal nociceptor broadly expressed in sensory neurons involved in pain sensation, thereby playing an essential role in analgesia ...

Loss-of-function mutations of the CFTR gene cause the life-shortening genetic disease cystic fibrosis (CF), whereas overactivity of CFTR may lead to secretory diarrhea and polycystic kidney disease.

This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a ...

Given the promising clinical value of allosteric modulators of G protein-coupled-receptors (GPCRs), mechanistic understanding of how these modulators alter GPCR function is of significance. Here, we ...

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...

Title: Addex Therapeutics Reports Q1 2026 Financial Results and Provides Corporate Update Date: June 25, 2026 Time: 16:00 CET ...

According to a recently published research paper, an approach has been developed to create artificial allosteric sites (where by binding an effector molecule, activity at the distal active site is ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

NEW YORK--(BUSINESS WIRE)--Allosteric Bioscience, Inc., announced today that Dr. Susan Michaelis has joined its Scientific Advisory Board (SAB). Dr. Michaelis is a leading scientist working on ...